Discoveries for alternative pathway-mediated diseases
Our game changing technology is supported by both venture and federal funding. NovelMed’s intellectual property includes several issued patents that cover our diverse therapeutic antibody landscape. We have advanced the selected humanized monoclonal antibody that binds and neutralizes the alternative pathway C3 and C5 convertases. Such a targeted approach blocks AP driven upstream and downstream formation of C3b, C3a, C5b, C5a, and MAC. We believe that our high affinity, high potency humanized monoclonal would control diseases where both C3b and MAC play a role in disease pathogenesis.